Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
19.05B
Market cap19.05B
Price-Earnings ratio
-6.04
Price-Earnings ratio-6.04
Dividend yield
Dividend yield
Average volume
17.27M
Average volume17.27M
High today
$50.92
High today$50.92
Low today
$46.84
Low today$46.84
Open price
$49.80
Open price$49.80
Volume
19.93M
Volume19.93M
52 Week high
$55.20
52 Week high$55.20
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 19.05B, Moderna(MRNA) trades at $48.58. The stock has a price-to-earnings ratio of -6.04.

On 2026-01-24, Moderna(MRNA) stock traded between a low of $46.84 and a high of $50.92. Shares are currently priced at $48.58, which is +3.7% above the low and -4.6% below the high.

Moderna(MRNA) shares are trading with a volume of 19.93M, against a daily average of 17.27M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.

MRNA News

Simply Wall St 12h
Moderna Recasts Growth Story Toward Oncology As Vaccine Prospects Blur

Moderna (NasdaqGS:MRNA) is reducing its focus on late stage vaccine development in the U.S. due to regulatory and market access hurdles. The company is redirec...

Moderna Recasts Growth Story Toward Oncology As Vaccine Prospects Blur
TipRanks 13h
Moderna’s Cancer Bets Ignite Powerful Stock Rebound

Moderna ( (MRNA) ) has risen by 16.45%. Read on to learn why. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smart...

TipRanks 1d
Moderna and Merck Advance Personalized mRNA Cancer Vaccine Into Phase 2 Bladder Cancer Trial

Moderna (MRNA) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

Analyst ratings

70%

of 27 ratings
Buy
14.8%
Hold
70.4%
Sell
14.8%

More MRNA News

Seeking Alpha 2d
Moderna cutting R&D on vaccines amid U.S. pushback: CEO

Moderna (MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back...

Moderna cutting R&D on vaccines amid U.S. pushback: CEO
TipRanks 2d
Moderna Stock Jumps 10% on Positive Results for Cancer Drug

Shares of drug maker Moderna (MRNA) are up 10% on Jan. 22 after the company reported positive trial results for its newest cancer drug. Claim 50% Off TipRanks...

Sherwood News 2d
Moderna extends rally on positive cancer vaccine results

Moderna extends rally on positive cancer vaccine results Moderna has more than doubled since it announced on Tuesday that its cancer vaccine reduced the risk o...

Moderna extends rally on positive cancer vaccine results
TipRanks 2d
Moderna curbs investment in vaccine trials due to U.S. backlash, Bloomberg says

Moderna’s (MRNA) chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations...

Simply Wall St 3d
Moderna Cancer Vaccine Data Extends Oncology Potential Beyond Covid Franchise

Moderna (NasdaqGS: MRNA) and Merck reported five year Phase 2b data for their personalized mRNA cancer therapy, intismeran autogene (mRNA-4157), combined with K...

Moderna Cancer Vaccine Data Extends Oncology Potential Beyond Covid Franchise
Benzinga 3d
Stock Market Today: S&P 500, Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft, Moderna, Intel In Focus

U.S. stock futures rose on Thursday following Wednesday’s gains. Futures of major benchmark indices were higher. The indices settled higher on Wednesday, gaini...

Stock Market Today: S&P 500, Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft, Moderna, Intel In Focus
TipRanks 3d
Moderna Stock Hits a New 52-Week High — Can the Rally Last Through 2026?

Moderna (MRNA) stock surged about 16% on Wednesday and hit a new 52‑week high of $50. The strong rally came after Moderna and Merck (MRK) released five‑year fol...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.